Alpha Deal Group initiates coverage on Addex Therapeutics

17 August 2015

Alpha Deal Group on Monday said it has initiated research on Addex Therapeutics (SIX: ADXN) saying the company’s value lies in its assets.

The broker in a research note said the company is poised to witnesses a strong rebound.

Switzerland-based Addex Therapeutics is engaged in the development of small molecule drugs. Its lead product, dipraglurant (ADX48621) has successfully completed Phase IIa in Parkinson’s disease levodopa-induced dyskinesia (PD-LID). In addition, dipraglurant is scheduled to start a Phase IIa in focal cervical dystonia. The company is also is advancing several preclinical programs.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK